Mohammad Krayem

Service(s) : Laboratoire d'oncologie chirurgie expérimentale

mohammad.krayem [at] bordet.be

Publications

Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit.

Auteurs : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Année : 2021
Journal : Mol Cancer Res

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>

Auteurs : Krayem M, Aftimos P, Najem A, Hooven TVD, Berg AVD, Hovestad-Bijl L, Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Année : 2020
Journal : Cancers (Basel)

Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms.

Auteurs : Soumoy L, Wells M, Najem A, Krayem M, Ghanem G, Hambye S, Saussez S, Blankert B, Journe F
Année : 2020
Journal : Biology (Basel)

Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis.

Auteurs : Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem G, Saussez S, Colet JM, Journe F
Année : 2020
Journal : Cancers (Basel)

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.

Auteurs : Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Année : 2020
Journal : Cancers (Basel)

Plus de publications »

Mohammad Krayem

Suivez-nous!

Images exclusives du nouvel Institut Jules Bordet !

Languages

Contact